HSPB1 and prostate carcinoma: Hsp27 overexpression has been described as an indicator of poor outcomes in patients with various cancer types including, non-small lung cancer, breast cancer, colorectal cancer, melanoma, glioma, prostate cancer, intrahepatic cholangiocarcinoma and hepatocellular carcinoma [27,28,29,30,31,32,34,41,42,63,79,137,138,139].